42 citations
,
January 2008 in “Clinical colorectal cancer” In this study, a combination of irinotecan and cetuximab showed varied response rates in metastatic colorectal cancer patients, with manageable skin toxicity that improved quality of life when treated collaboratively by oncology and dermatology teams.
5 citations
,
April 2016 in “PubMed” This article discusses common skin side effects of EGFR inhibitors like cetuximab, noting their management remains based on clinical experience without strict therapy protocols, but provides no new clinical findings.
30 citations
,
March 2007 in “Expert opinion on drug safety” This review discusses recommendations for managing cetuximab-induced rash in metastatic colorectal cancer treatment and highlights the lack of standardized treatment plans based on clinical evidence.
12 citations
,
February 2010 in “Journal of The American Academy of Dermatology” This article discusses the use of cetuximab for recurrent squamous cell skin cancer in palliative care, noting good responses but frequent cutaneous side effects; it presents no new findings.
3 citations
,
August 2019 in “Journal of Cancer Research and Therapeutics” This case report describes an unusual combination of hypertrichosis, androgenic alopecia, and trichomegaly in a patient with metastatic colon adenocarcinoma treated with cetuximab, with no adrenal or hormonal abnormalities detected.